Key Takeaways Agonism Profile: Tirzepatide is a dual GLP-1/GIP agonist, while Retatrutide is a "triple agonist" targeting GLP-1, GIP, and Glucagon receptors
AHK-CU is a copper-binding tripeptide that has gained attention in regenerative research for its potential role in supporting hair follicle biology, skin renewal, and extracellular matrix remodeling
Its a triple agonist it hits GLP-1, GIP and glucagon receptors, adding a metabolism-boosting effect on top of appetite control (GoodRx)
People who use Zepbound or Mounjaro, the dual-agonist medications, lose an average of about 20% of their body weight, while those who take Ozempic or Wegovy, the single-agonist drugs, lost an average of about 14% of their body weight
FAQ Can I take NAC and glutathione at the same time
The mechanisms that produce meaningful results, including collagen remodeling, growth hormone optimization, tissue repair, and metabolic recalibration, take time to develop fully